Complex patterns of human antisera reactivity to novel 2009 H1N1 and historical H1N1 influenza strains

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Carter, Donald M ^a   Lu, Hai Rong ^a   Bloom, Chalise E ^a   Crevar, Corey J ^a   Cherry, Joshua L ^b   Lipman, David J ^b   Ross, Ted M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CROSS REACTION; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; INFANT; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; NONHUMAN; PRESCHOOL CHILD; SCHOOL CHILD; VIRUS ISOLATION; VIRUS STRAIN;

ANTIBODIES, VIRAL; CROSS REACTIONS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNE SERA; INFLUENZA A VIRUS, H1N1 SUBTYPE; SPECIES SPECIFICITY; VIRAL VACCINES;

ORTHOMYXOVIRIDAE;

EID: 84863995590     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039435     Document Type: Article

References (30)

1. Reid AH, Fanning TG, Hultin JV, Taubenberger JK, (1999) Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene. Proc Natl Acad Sci U S A 96: 1651-1656.
2. Reid AH, Fanning TG, Janczewski TA, Taubenberger JK, (2000) Characterization of the 1918 "Spanish" influenza virus neuraminidase gene. Proc Natl Acad Sci U S A 97: 6785-6790.
3. Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solorzano A, et al. (2005) Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310: 77-80.
4. Scholtissek C, Rohde W, von Hoyningen V, Rott R, (1978) On the origin of the human influenza virus subtypes H2N2 and H3N2. Virology 87: 13-20.
5. McVernon J, Laurie K, Barr I, Kelso A, Skeljo M, et al. (2011) Absence of cross-reactive antibodies to influenza A (H1N1) 2009 before and after vaccination with 2009 Southern Hemisphere seasonal trivalent influenza vaccine in children aged 6 months-9 years: a prospective study. Influenza Other Respi Viruses 5: 7-11.
6. McVernon J, Laurie K, Nolan T, Owen R, Irving D, et al. (2010) Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October- December 2009. Euro Surveill 15.
7. Presanis AM, de Angelis D, Hagy A, Reed C, Riley S, et al. (2009) The severity of pandemic H1N1 influenza in the United States, from April to July 2009: a Bayesian analysis. PLoS Med 6: e1000207.
8. Reed C, Angulo FJ, Swerdlow DL, Lipsitch M, Meltzer MI, et al. (2009) Estimates of the prevalence of pandemic (H1N1) 2009, United States, April-July 2009. Emerg Infect Dis 15: 2004-2007.
9. Zimmer S, Crevar C, Carter D, Stark J, Giles B, et al. (2010) Seroprevalence Following the Second Wave of Pandemic 2009 H1N1 Influenza in Pittsburgh, PA, USA. PLOS One 5: e11601.
10. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE Jr, et al. (2010) Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus. Science.
11. Zhang W, Qi J, Shi Y, Li Q, Gao F, et al. (2010) Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus. Protein & Cell 1: 459-467-467.
12. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, et al. (2009) Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza Virus. New England Journal of Medicine 361: 1945-1952.
13. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-1025.
14. Chowell G, Bertozzi SM, Colchero MA, Lopez-Gatell H, Alpuche-Aranda C, et al. (2009) Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 361: 674-679.
15. Krause JC, Tumpey TM, Huffman CJ, McGraw PA, Pearce MB, et al. (2010) Naturally Occurring Human Monoclonal Antibodies Neutralize both 1918 and 2009 Pandemic Influenza A (H1N1) Viruses. The Journal of Virology 84: 3127-3130.
16. Manicassamy B, Medina RA, Hai R, Tsibane T, Stertz S, et al. (2010) Protection of Mice against Lethal Challenge with 2009 H1N1 Influenza A Virus by 1918-Like and Classical Swine H1N1 Based Vaccines. PLoS Pathog 6: e1000745.
17. Skountzou I, Koutsonanos DG, Kim JH, Powers R, Satyabhama L, et al. (2010) Immunity to Pre-1950 H1N1 Influenza Viruses Confers Cross-Protection against the Pandemic Swine-Origin 2009 A (H1N1) Influenza Virus. The Journal of Immunology 185: 1642-1649.
18. Scholtissek C, von Hoyningen V, Rott R, (1978) Genetic relatedness between the new 1977 epidemic strains (H1N1) of influenza and human influenza strains isolated between 1947 and 1957 (H1N1). Virology 89: 613-617.
19. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, et al. (2009) Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361: 1945-1952.
20. Davenport FM, Hennessy AV, Francis T, (1953) Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med 98: 641-656.
21. Davenport FM, Hennessy AV, Francis T, (1957) Influence of primary antigenic experience upon the development of a broad immunity to influenza. Trans Assoc Am Physicians 70: 81-90.
22. Francis T, (1952) Significance of antigenic variation of influenza viruses in relation to vaccination in man. Fed Proc 11: 808-812.
23. Jensen KE, Francis T, (1953) The antigenic composition of influenza virus measured by antibody-absorption. J Exp Med 98: 619-639.
24. Giles BM, Bissel SJ, DeAlmeida DR, Wiley CA, Tumpey TM, et al. (2011) A 1918 influenza virus-like particle elicits long-lasting protective immune responses to 2009 pandemic H1N1 virus.
25. Gillim-Ross L, Subbarao K, (2006) Emerging respiratory viruses: challenges and vaccine strategies. Clin Microbiol Rev 19: 614-636.
26. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, et al. (2005) Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366: 1175-1181.
27. Bright RA, Ross TM, Subbarao K, Robinson HL, Katz JM, (2003) Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. Virology 308: 270-278.
28. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI, (2006) Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295: 891-894.
29. Mitchell JA, Green TD, Bright RA, Ross TM, (2003) Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 21: 902-914.
30. Ross TM, Xu Y, Bright RA, Robinson HL, (2000) C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 1: 127-131.